A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
Patrocinador(es) del estudio: Walter Reed Army Institute of Research (WRAIR)
Números de identificación: NCT00004579, RV124
Propósito del estudio
To describe the safety, tolerability, and immunogenicity of ALVAC-HIV (vCP205) administered alone or boosted with a clade B oligomeric gp160MN/LAI-2 in HIV seronegative volunteers to include: (1) 3 different dosages of gp160MN/LAI-2; (2) 2 adjuvants: PCPP and alum; and (3) the co-administration of vCP205 boosted by vCP205 plus gp160.
|Infecciones por el VIH |
Seronegatividad para el VIH
Criterios de exclusión
Volunteers will not be eligible for this study if they:
Have ever been given an HIV vaccine or certain other vaccines. (However, rabies vaccines are allowed.)
Participate in activities that place them at high-risk for HIV infection, such as injection drug use or unprotected sex with someone who has HIV infection.
Have certain psychiatric, medical, or substance abuse problems.
Are allergic to eggs or other vaccines.
Are an employee at a participating site and have access to study information.
Are taking certain medications.
Have received blood transfusions within 3 months before entering this study.
Are pregnant or breast-feeding.
Centros de estudio/contactos
Walter Reed Army Institute of Research, Rockville, Maryland, United States
Actualizado: 29 de abril del 2003